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Abstract 
 
Introduction 
Chemokine receptors belong to the family of G protein-coupled 
receptors. To date, the chemokine system is made up by 50 ligands 
and 21 receptors, classified on the basis of the cysteine pattern of the 
chemokines. CCR2 and its endogenous ligand CCL2 have been found 
to be involved in several diseases such as multiple sclerosis, 
rheumatoid arthritis, metabolic diseases, cancer and neuropathic pain. 
In these years different treatments have been proposed to inhibit the 
chemokine system from mAb to small molecules. Unfortunately, no 
cures are available on the market yet.  
 
The aim of this project is to elucidate the binding site of two small 
molecule antagonists of CCR2 chemokine receptor: V-10-5191 and 
V-10-5299. The present project was fully planned and carried out in 
the laboratories of the Division of Medicinal Chemistry, 
Leiden/Amsterdam centre for Drug Research (LACDR), Leiden 
University (The Netherlands). 
Methods 
Site-directed mutagenesis and two different techniques of 
transfections: calcium phosphate and PEI transfection in HEK-293 
cells were performed to express the receptor in study. Radioligand 
binding assays were applied to investigate the binding site of the 
molecules. 
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Results 
Between the two transfection techniques evaluated only the polycation 
PEI transfection method yielded CCR2 expression for which 125I-
CCL2 binding could be detected. Subsequently the mutants Y49A1.39, 
W98A2.60, Y120A3.32, H121A3.33, F125A3.37, I208A5.44, I263A6.55, 
E291A7.39, E291Q7.39, T292V7.40 were evaluated using 125I-CCL2 and 
the tritium derivatives of two small molecules [3H]-V-10-5191 and 
[3H]-V-10-5299. Mutants Y49A1.39, W98A2.60, Y120A3.32, E291A7.39 
were found to be important for 125I-CCL2 binding. For [3H]-V-10-
5191 the mutants Y49A1.39, W98A2.60 and T292V7.40 showed a 
significant decrease in specific binding followed by residues 
Y120A3.32, E291A7.39 and E291Q7.39. Because of the large standard 
deviation no certain binding mode can be evaluated for the [3H]-V-10-
5299. However binding of [3H]-V-10-5299 seemed to be less affected 
by any of the mutations in comparison to [3H]-V-10-5191. 
 
Conclusion 
A better understanding of the binding site of antagonist of chemokine 
receptor can improve the knowledge in the pharmacological profile of 
the molecules in study and also give suggestions for the synthesis of 
further antagonist of CCR2 chemokine receptor. 
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Introduction 
Chapter 1 
GPCRs 
 
1.1. An overview of proteins as receptors 
The cells of our body can be compared with the worldwide human 
population; to understand each other they need to communicate. 
Among all the characters, the protagonists that play a crucial role in 
this communication system are the receptors. The receptors are 
proteins, localized on the surface of the cell membrane, across the cell 
membrane or in the cytosol. They are able to perform their task only 
after the interaction with a chemical messenger, which could be 
another protein, a hormone and also a small molecule as a drug. The 
chemical messenger is called ligand and can bind in several ways. The 
exact position in which this interaction takes place is known as 
binding site while the general area is known as binding region [2]. 
The interaction between these two parts triggers a cascade of events 
that leads to a series of biological effects inside the cells. There are 
some ligands soluble in lipids, such as steroid hormones and non-
steroid hormones. They are able to diffuse across the membrane, bind 
the cytosolic receptor, form a complex ligand-receptor and go into the 
cell nucleus where they modulate DNA transcription. However, most 
of the ligands such as amines, amino acids, peptide and proteins are 
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soluble in water. Because of their hydrophilic nature, they are not able 
to diffuse across the cell membrane and therefore they bind to the 
extracellular site of a transmembrane receptor. These ligands are also 
called primary messenger, because they evoke the activation of an 
intracellular site of the receptor that interacts with another protein. 
This protein stimulates the release of a second messenger, which 
promotes the amplification of cellular signal and leads towards the 
final response. One family of receptors that follows this mechanism of 
action is the family of G-protein coupled receptors (GPCRs). This is 
the largest, the most ubiquitous and the most versatile family of 
membrane receptors, which is also the most common target of 
therapeutic drug [3]. The next paragraph is focussed on the GPCR 
classification, structure and functional characteristics. 
 
1.2. GPCRs: classification and structure 
GPCRs represent a productive area for drug discovery. As reported in 
literature, chemical programs to target GPCRs accounted for 40% of 
the portfolio of the pharmaceutical industry, with nearly 40% of these 
in clinical development [4]. It has been estimated that the human 
genome encodes more than 1000 GPCRs [5]. Structural studies 
revealed that GPCRs, as all transmembrane receptors, have three 
distinct domains [5]: 
 
- an extracellular domain 
- a transmembrane domain 
- an intracellular domain 
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These different regions prove the amphipathic nature of this class of 
receptors. The hydrophilic extracellular and intracellular domains, 
containing polar and ionic side chain amino acids, can interact with 
the aqueous environment. The transmembrane domain, containing 
non-polar amino acids whit a α-helix tertiary structure, crosses the 
double phospholipidic stratus. GPCRs are members of the superfamily 
of the 7TM receptors and can be recognised from the precise number 
of transmembrane regions. The features that reveal a general common 
tertiary structure (Fig. 1) are: N-terminus domain, three loops in the 
extracellular region, C-terminus domain, three loops in the 
intracellular region and seven transmembrane regions with an α-helix 
structures [5]. 
 
 
Fig. 1 Structure of 7TM GPCRs [3]. 
 
There are extensive amino acid sequence similarities that divide 
GPCRs into different classes, each with characteristic highly 
conserved residues, which define similar motifs. For example, in the 
large class of the rhodopsin receptor e.g. we have the DRY motif at 
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the cytoplasmatic end of the third transmembrane domain and prolines 
at the specific positions in helices 5, 6, 7 [5]. 
According to the Receptor Nomenclature and Drug Classification 
provided by the International Union of Pharmacology Committee, the 
superfamily of GPCRs is divided in different families or classes on the 
basis of their similarity. The main are: A, B, C or classes I, II, III 
respectively [6]. 
Each family generally shares over 25% sequence identity in the 
transmembrane core region, and a different set of highly conserved 
residues and motifs [5]. 
Family A (Class I) is by far the largest group and includes rhodopsin 
receptor, histaminic, adrenergic, dopaminergic and muscarinic 
receptors, the olfactory receptors. These receptors are characterized by 
the presence of cystein esterificated with the palmitic group at the C-
terminus tail [5]. 
Family B (Class II) contains about 25 members including the 
gastrointestinal peptide hormone family, corticotropin-releasing 
hormone family, calcitonin and parathyroid hormone family. A long 
tail, including six conserved cysteins connected by disulfure bond, 
characterizes the N-terminus domain and is also involved in ligand 
binding. Receptors of this family seem to be mainly coupled with a G 
protein having a Gs subunit [5]. 
Family C (Class III) is quite small and includes the metabotropic 
glutamate receptor family, GABA receptor and the calcium sensing 
receptor. They are characterized by large extracellular amino terminus 
domain important for ligand binding and activation [5]. 
Endogenous ligands have been also identified for approximately 210 
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GPCRs, but for almost 100 receptors they have been not proposed yet. 
For this reason scientific community calls them “orphan receptor”, 
which represent an attractive field for pharmaceutical industry as 
target for future drug discovery [7]. 
 
1.3. GPCRs: receptor activation and signalling 
The classical 7TM receptor signalling explains as in absence of a 
ligand, 7TM receptors are in a low–affinity state. After ligand binding, 
a transient high affinity tertiary complex of ligand, activate receptor 
and G protein is formed. G proteins are a family of membrane-
associated proteins, so called because they bind GDP and GTP. It has 
been found that they are heterotrimeric proteins, containing a α 
subunit responsible for GDP and GTP binding and a, β and γ subunit, 
associated in a dimeric βγ complex. The α subunit has intrinsic 
GTPase activity and is therefore able to hydrolyse GTP. After the 
binding of the ligand to the receptor, a series of conformational 
changes takes place and the high affinity ternary complex mentioned 
above is formed (Fig. 2). GDP is released from the G protein and is 
replaced by GTP. This leads to dissociation of the G-protein complex 
into α subunit and βγ dimers, which both activate several effectors. 
Hydrolysis of GTP to GDP, a process regulated by RGS (regulator of 
G – protein signalling), leads to the reassociation of the three subunits 
and the end of the activation cycle. In order to improve this 
understanding step by step, but also to verify if a receptor is still 
functional or not, this mechanism has been investigated in several 
ways. Among the different assays the [35S]-GTPγS functional assay, is 
one of the most widely used [7]. 
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Fig. 2 GPCRs activation mechanism [7]. 
 
Detailed studies revealed that G proteins are extremely complex. To 
date each of these subunits is known to be a member of a gene family. 
It has been identified twenty different α subunits, six β subunits and 
twelve γ subunits. G- proteins are generally classified on the basis of 
their α subunits. Among all of them, the main subfamilies are: Gs 
proteins coupled to stimulation of adenylyl cyclase; Gi that provokes 
inhibition of adenylyl cyclase and the activation of some potassium 
channel such as GIRK (G protein coupled inwardly rectifying 
potassium channel); Gq coupled to the activation of phospholipase Cβ 
that provokes the release of DAG and IP3 as second messengers; Go 
which reduces the probability of the activation of some voltage 
dependent Ca2+ channel involved in neurotransmitters release and 
G12/13 coupled to the activation of RhoGEF (Guanine-nucleotide 
exchange factor) (Fig. 3) [7]. 
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Fig. 3 GPCRs signaling pathways [7] 
 
As documented by several studies GPCR signalling extended far 
beyond the traditional model of: “binding of agonist to the receptor à 
G protein activation à effector”. It can also be regulated by 
desensitization and internalization, a process that involves 
phosphorylation, complex formation with the β-arrestin protein, 
recruitment of the resultant complex to clathrin-coated pits, 
endocytosis and at the end recycling to the membrane or lysosomal 
degradation. Receptor desensitization is a process that protects the 
cells against both the acute and the chronic overstimulation by the 
agonist. This mechanism operates at the level of the receptor, 
mediated by kinases (such as PKA and PKC) that provoke the 
uncoupling of G protein, but also at the level of the G protein [8]. 
The family of proteins RGS (regulator to G protein signalling) 
increases the rate of GTP hydrolysis bound to both Gi and Gq α-
subunits, as reported for the protein RGS12 on CXCR2 [8]. 
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Phosphorilation can be mediated by GRKs, a family of kinase having 
seven serin and threonin residues. However, while the first 
phosphorilation mechanism occurs also on non-activated receptor, the 
second mechanism acts only on the agonist-activated-GPCRs. GRKs 
phosphorilation is important for receptor internalization. In fact it 
leads to the recruitment of β-arrestin to the receptor and targets the 
receptor-β-arrestin complex to clathrin-coated pits. When 
internalization takes place, the receptor is incorporated in an 
endosome. Here it can have different destinies: one is the 
dephosphorylation and the recycling to the cell surface and another 
one is the degradation in lysosomes that leads to a process known as 
down regulation. It seems that β-arrestin also regulates 7TM receptor 
trafficking. Recent evidence indicates that β-arrestin internalization is 
necessary for down regulation, mediated by the binding of the β- 
arrestin lysine residues to single or multiple ubiquitins. This process, 
known as ubiquitination, directs the target protein to a proteosome for 
their destruction. Likewise, for the CXCR4 chemokine receptor, this 
process is important for the lysosomal sorting [9] [10]. 
The involvement of all these proteins and many others 
adaptor/scaffolding proteins that leads to the activation of several 
pathways, such as the ERK/MAPK cascade, show us the complexity 
and the compartmentalization of GPCRs signalling. The time frames 
of all these processes extend from seconds (phosphorylation), minutes 
(endocytosis) to hours (down regulation) [8]. 
This could also be important if we consider that the number of 
receptors may change over time such as in the course of a therapeutic 
treatment resulting in a down regulation, but also in some pathologic 
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conditions (neurodegenerative or inflammatory diseases) resulting in 
an up regulation. This is the case for the chemokine receptor. 
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Chapter 2 
Structure, function, and inhibition of chemokines 
 
2.1. The Chemokine System 
Chemokines (Greek – kinos movement) or chemotactic cytokines are a 
large family of small soluble proteins (approximately 8-12kDa in 
size), which play a fundamental role in human physiology from 
embriogenesis to inflammatory response. They are released by 
leukocytes and their main role is chemotaxis, characterized by a 
concentration gradient that leads immune cells such as leukocytes, 
monocytes and neutrophilis towards the target tissue [11]. 
 
 
Fig. 4 A model of a hypothetical interaction between a chemokine (pink) and his receptor (blue) 
based on the solved structured of chemokine and bovine rhodopsine [11]. 
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Based on their functionality, chemokines are classified as homeostatic 
chemokines constitutively expressed and inflammatory chemokines 
released after a pro-inflammatory stimulus (e.g. bacterial and virus 
infection or physical damage) by circulating leukocyte. It has been 
found that some of them also play a role in development, such as the 
development of the central nervous system, cardiogenesis and 
angiogenesis [12]. 
The structures of several chemokines have been solved by NMR and 
X-ray crystallography. Despite of their variable sequence homology, 
from less than 20% to over 90%, they have similar common features. 
Some conserved residues are important for their typical tertiary 
structure characterized by: a N-terminus of 6-10 amino acids, an N-
loop ending with a single turn helix called 310-helix, a three stranded 
β-sheet and a C-terminal helix. After translation some chemokines are 
secreted from the cells while others remains bound to the cell surface. 
Chemokine classification is based on the pattern of cystein residues in 
the ligands. Most of them have four cysteins that form one disulfide 
bound between the first and the third cystein and a second one 
between the second and the fourth. These covalently bound cysteins 
give a typical Greek key structure to the ligands. According to the 
system of nomenclature introduced to identify chemokines and their 
receptors, there are four subfamilies: C, CC, CXC and CX3C (C 
represents cystein and Xn the number of noncystein residues). To date 
more than 50 chemokines and 21 chemokine receptors have been 
identified. It has been found that several chemokines can interact with 
different chemokine receptors, and one receptor is able to bind several 
different chemokines. For this reason chemokine system was 
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described as redundant, but this promiscuity can suggest the 
complexity and the subtlety of the chemokine system [11]. 
A general mechanism of leukocyte recruitment after a tissue injury or 
an infection consist of: 
 
1. local up-regulation of pro-inflammatory chemokines in response 
to a signalling molecule such as TNF-α or IFN-γ; 
2. binding of the chemokine to GAGs in the endothelian cell 
surface as a mechanism of retention at the inflammatory site 
[13]; 
3. binding of the chemokine to the receptor expressed on leukocyte 
cell surface; 
4. activation of leukocyte receptor, increase in adhesiveness, 
extravasation of leukocytes from the blood; 
5. migration of leukocyte towards chemokine gradients to the site of 
injury or infection. 
 
Interaction chemokine-receptor has been described previously [14] 
dealing with a two-site model. It is hypothesized that the chemokine 
globular core binds to the extracellular N-terminus domain and the 
extracellular loops of the receptor. Otherwise the first residues of the 
N-loop of the ligand activate the receptor binding in the TM regions 
and some extracellular loops of the receptor (e.g. the DRY motif in 
the second extracellular loop) (Fig. 4). 
The chemokine receptor is the largest family of G-protein coupled 
receptor and they share all the structural and functional features of this 
protein superfamily, widely discussed in the previous chapter. 
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However, since the determination of the first GPCR crystal structure 
of bovine rhodopsin [15] much progress has been made in the 
knowledge of chemokine/ligands-receptor interaction or more in 
general for GPCRs. It was followed by the first structures of liganded 
GPCRs for the β-adrenoceptors and adenosine A2A receptor [16] [17] 
[18] and recently the CXCR4 chemokine receptor crystal structure 
was also solved [1], showing several differences to previous solved 
GPCRs. This has been revealed very important for mutagenesis and 
alignment study of chemokine receptor (Appendix) giving a wide 
impetus in chemokine drug discovery. 
 
2.2. CCR2 chemokine receptor 
Chemokine Receptor 2 represents a high–affinity receptor for the 
endogenous ligand MCP-1 (monocyte chemoattractant protein-1), 
cloned in the 1994 by Charo et al. [19] and also recognised as CCL2. 
It is the most characterized CCR2 ligand, but other member of 
macrophage chemotactive protein family of the chemokine 
(MCPclass), such as CCL8 (MCP2), CCL7 (MCP3), CCL13 (MCP4) 
bind to the same receptor [20]. The CCR2 receptor is present in 
mononuclear cells, basophils, memory T-cells, immature dentritic 
cells and Natural Killer cells. The alternative splicing of the 
carboxylic-terminal tail of gene encoding CCR2 generate two types of 
CCR2 receptors: type A CCR2a and type B CCR2b [19]. Further 
studies by Wong and co-workers showed that CCR2a is 
predominantly localized in the cytoplasm whereas CCR2b is exposed 
to cell surface [21]. It can activate the subunits Gαi and Gq of the 
trimeric G-proteins. The CCL2-CCR2 axis has been found to be 
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involved in several diseases: autoimmune diseases such as rheumatoid 
arthritis [22] and multiple sclerosis [23], metabolic diseases such as 
obesity and type II diabetes [24], respiratory diseases such asthma, 
allergic rhinitis [25], but also in cancer [26]. Recently it has been 
found that CCR2 has an important role in the neuropathic pain [27] 
and our attention is focused on this disease. 
 
2.3. Neuropathic pain 
Pain is a physiologic condition that occurs in response to adverse 
stimuli, but sometimes can evolve in pathological conditions due to 
damages to the nervous system, diabetes, cancer, toxic effects of drugs 
and infectious agent. These events can provoke an incorrect message 
on the nociceptive signal, leading towards a development of a 
spontaneous sensation of chronic pain, and sometimes excessive 
compared to the original stimulus (allodynia). The mechanism in 
which the chronic pain occurs shows first an up-regulation of the 
CCL2 by cell types of the peripheral nervous system such as, 
Schwann cells, resident macrophages, endoneurial fibroblasts and 
primary afferents of the dorsal root ganglia (DRG). The CCR2 
signalling in DRG in neurons is exicitatory and therefore 
pronociceptive. Then, DRG neurons may transport CCL2 to central 
nerves ending of the spinal cord where it is released. Once here CCL2 
can activate secondary neurons and some leukocytes expressing 
CCR2 [27]. 
It has been found that administration of exogenous CCL2 in spinal 
neurons can inhibit the activation of ionic current generated by 
stimulation of GABAa receptor [28]. Neuromodulation of GABAergic 
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inhibition could have facilitation in nociceptive transmission [29]. 
This means that CCL2 is a modulator of the nociceptive information 
in both peripheral and central nervous system. Knockout mice 
deficient in CCR2 receptor have also supported the latter mechanism 
and the role of CCL2/CCR2 axis in neuropathic pain. Testing of acute 
pain behaviour in CCR2 KO mice does not differ from WT mice. 
CCR2 KO mice did not show mechanical allodynia induced by partial 
ligation of the sciatic nerve, a model known induced 
hypernociception, or intraplantar administration of CCL2 [30]. 
Whereas overexpression of glial CCL2 show enhanced pain 
sensitivity [31]. White et al. [27] examined the possibilities that DRG 
could be the site of CCL2 action. Using two models of neuropathic 
pain: ligation of sciatic nerve and chronic compression of the DRG 
(CCD), an overexpression of CCL2 was provoked, suggesting that 
sensitive neurons themselves might be the site of chemokine receptor 
activation in the generation of chronic pain [32]. There are many 
factors involved in the pathophysiology of neuropathic pain but these 
findings showed how an intervention on CCL2/CCR2 axis could be 
important in the therapeutic treatment. 
 
2.4. Therapeutic treatment of chemokine-involved 
diseases 
Several inhibitors of the chemokine system have been developed with 
different biological and chemical profiles. The inhibitors investigated 
extended from monoclonal antibody, natural proteins encoded by viral 
genomes, gene therapy, antisense inhibitors, to small molecule 
binding to the target receptor [12]. For CCR2 a monoclonal antibody 
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MLN1202 has been developed by Millennium Pharmaceuticals. It has 
been in clinical trials for several diseases such as: metastatic cancer, 
atherosclerosis cardiovascular diseases and multiple sclerosis, but was 
not successful. mAb-derived therapeutics seems to be difficult to 
apply. The limited availability of GPCRs as purified proteins, and 
their low immunogenicity as TM proteins make arduous the 
generation of antibody able to recognise the GPCRs epitope [33]. 
More successful has been the research in small molecule antagonist of 
chemokine receptors. Indeed our attention will be focused on them. 
 
2.5. Binding mode of small molecule antagonist of 
chemokine receptors 
Surgand and co-workers [34] identified two binding pockets in the 
TM helices of the receptor: a minor and major binding pocket 
localized between TM1, 2, 3, 7 and TM3, 4, 5, 6 respectively. 
Moreover, Andrew et al. [35] generated a chimera receptor of CCR4-
CCR5 showing how an intracellular binding site, localized in the helix 
8, is important for the binding of aryl sulphonamides designed by 
Glaxo. As Kenakin reported [36]: GPCRs signalling is allosteric by 
nature because the endogenous agonist and the G proteins act as 
mutual allosteric modulators. However also small molecule can 
interact in this system as both in orthosteric and allosteric sites [37] 
[38] and they can show a competitive/surmountable or non-
competitive/insurmountable behaviour [39]. As known, orthosteric 
sites (from Greek “ortho” means normal, correct or straight) binds to 
the endogenous ligand; whereas, the allosteric site is different from 
the active site (from Greek “allo” means other), and his activation can 
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generate conformational changes and alters important parameters such 
as affinity and efficacy of the receptor. Several pharmaceutical 
companies such as Merck, Johnson & Johnson, Glaxo, Novartis, 
Roche, Chemocentryx, Incyte/Pfizer showed their interest and 
invested in the field of CCR2 antagonists.  Some of their compounds 
reached clinical trials phase II: such as MK-0812 and MLN1202 
synthesized by Merck for atherosclerosis, MS and cancer, BMS-
741672 by Bristol Myers Squibb for neuropathic pain, JNJ17166864 
by Johnson & Johnson for allergic rhinitis and PF-04136309 by 
Incyte/Pfizer for pain. Despite these molecules showed a satisfactory 
outcome, other showed a lack in term of efficacy. One of the crucial 
points in development of CCR2 antagonists is the limited sequence 
homology (about 85%, Appendix), between murine CCR2 and human 
CCR2. Johnson & Johnson have reported large shift in potency for 
some of their compound between human and murine receptors [40]. 
This aspect can represent an obstacle in the evaluation of the CCR2 
antagonists in preclinical rodent models. However Incyte developed a 
molecule INCB3344 or V-10-5191 having a good affinity on both 
human and mouse receptor, with a potency of 10nM to inhibit 125I-JE 
(JE = murine CCL2) [41] and an IC50 (half maximal inhibitory 
concentration)  of 7nM for hCCR2b determined with binding assays 
by Shin et al, 2009  [42]. The same molecule showed an in vivo 
inhibition or macrophage recruitment in mouse model of DTH and 
EAE and rat model of adjuvant arthritis [43]. The pharmacological 
profile of the CCR2 antagonist described ranges from a competitive 
such as for INCB3344 [44] to non-competitive behaviour such as for 
JNJ-141491 (J&J) [45]. However the most advisable manner is an 
insurmountable antagonism instead of a surmountable antagonism. 
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This is because the effect of the antagonist will be not overcome by 
higher doses of agonist from the receptor, leading towards better 
therapeutic aims [40]. Some features that characterize the interaction 
ligand-receptor are important to reach this purpose: allosteric 
interaction, non-competitive behaviour and a long receptor 
dissociation time also recognised as residence time. 
 
2.6. Mutagenesis studies 
To better understand the way in which a ligand binds to his receptor is 
to modify amino acidic residues and analyse the effects that the 
translated protein provokes, a process also recognised as mutagenesis. 
In site-directed mutagenesis single genes are engineered to produce 
mutant proteins. The site-directed approach may be done in such 
technique as alanine-scanning mutagenesis whereby residues are 
systematically mutated to alanine in order to identify residues 
important to the structure or function of a protein. Thanks to the help 
of a receptor homology model, it is also possible to rationalize the 
results and improve the next development in the discovery of new 
molecules with a better pharmacological outline. Otherwise some 
mutations can occur naturally in human genomic pattern and provoke 
pathological states. They are known as single nucleotide 
polymorphisms (SNPs). Considering CCR2, Bektas et al. found that G 
allele of CCL2 and 64I allele of CCR2 may be risk factors for oral 
squamous cell carcinoma [46]. Lin HL et al. also showed that one A 
allele of the V64I CCR2 gene polymorphism increased risk of 
cardiovascular diseases [47]. Many others SNPs have been found to 
represent risks in diseases such as hepatocellular carcinoma [48]; 
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preeclampsia, a condition that can complicate pregnancy [49]; cervical 
cancer [50], etc. These list of SNPs are just an example that suggest 
how analysis in natural mutations could also help in a better 
understanding of CCL2-1/CCR2 axis, but also improve the knowledge 
of ligand-receptor interactions leading towards the design of more 
efficient drugs. 
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Aim of the project 
 
The present project was fully planned and carried out in the 
laboratories of the Division of Medicinal Chemistry, 
Leiden/Amsterdam centre for Drug Research (LACDR), Leiden 
University (The Netherlands). 
The study is focused on two small molecule antagonists of hCCR2b: 
INCB3344 or V-10-5191 [44] and V-10-5299 [51]. Ten mutants of 
hCCR2 (Y49A1.39, W98A2.60, Y120A3.32, H121A3.33, F125A3.37, 
I208A5.44, I263A6.55, E291A7.39, E291Q7.39, T292V7.40) were kindly 
provided by J. Pease and will be used to get insight into the binding 
sites of V-10-5191 and V-10-5299. These mutants have been 
predicted by computational modelling by Hall et al. [52] to be 
involved in the binding of dual antagonists of human CCR5/CCR2: 
TAK-779 (N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-
5Hbenzohepten-8-yl] carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-
aminium) and Teijin compound 1 (N-(carbamoylmethyl)-3-
trifluoromethyl-benzamido-parachlorobenzyl 3-aminopyrrolidine). 
Comparison between two different techniques of transfection in 
mammalian HEK-293 cells: calcium phosphate and PEI transfection, 
will lead to the better expression of the receptor. The expression of the 
receptor will be checked using 125I-CCL2, [3H]-V10-5191 and [3H]-V-
10-5299 in radioligand binding assays. The analysis of the effects of 
these mutants on specific binding will add information on the 
chemical interactions that occurs between the residues involved in the 
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binding site and the three molecules. These data could support further 
studies in the design of new antagonists of chemokine receptor CCR2, 
improving the knowledge on the binding site of GPCRs and clarify the 
pharmacological profile of the molecules already known. 
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Chapter 3 
Materials and methods 
 
3.1. Chemical and reagents 
The CCR2-specific antagonists, ligand V-10-5191 also recognized as 
INCB3344 and V-10-5299 were kindly provided by Vertex 
Pharmaceutical incorporated (San Diego, CA). The unlabelled 
endogenous ligand CCL2 was purchased from PeproTech (Rocky 
Hill, NJ). The radiolabeled tritium compounds [3H]-V-10-5191 
(specific activity 32 Ci mmol-1) and [3H]-V-10-5299 (specific activity 
64 Ci mmol-1) were kindly provided by ViTrax (Placentia, CA), and 
the iodinate endogenous radioligand 125I-CCL2 (specific activity 2200 
Ci mmol-1) was provided by Perkin-Elmer (Waltham, MA). Poly-D-
Lysine was provided by Invitrogen. The monoclonal HA-tag 
EPITOPE antibody was purchased by Novels Biologicals (Cambridge, 
UK) and the secondary antibody conjugated goat anti-rabbit by 
Novels Biologicals (Cambridge, UK). Linear PEI (MW 25000Da) was 
purchased from Polysciences, Inc. Albumin standard and BCA 
Reagents were purchased from THERMO Scientific, USA. All other 
reagents were of the highest purity available and were obtained from 
standard commercial sources. 
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3.2. DNA constructs 
The cDNA encoding human chemokine (C-C motif) receptor 2 
(CCR2) WT and mutants (Y49A1.39, W98A2.60, Y120A3.32, H121A3.33, 
F125A3.37, I208A5.44, I263A6.55, E291A7.39, E291Q7.39, T292V7.40) 
having a sequence of 3xHA-tag encoded at the N-terminus tail were 
subcloned into pcDNA3.1 as a vector containing ampicillin resistence 
gene and kindly provided by J. Pease (http://www.cdna.org). WT 
CCR2 lacking the HA-tag was kindly provided by VU University (M. 
Smit). All constructs were verified by DNA sequencing, using 
program BLASTIN 2.2.26 + BaseClear, before use. 
 
3.3. Transformation of competent cells: E. coli DH5α  
In order to produce large amounts of identical DNA, plasmid DNA 
having the constructs on study were introduced in prokaryotic cells: E. 
coli DH5α stored in 20% of glycerol at -80°C (purchased by 
Invitrogen). A Heatshock at 42°C was used in order to make 
competent bacterial cells. Transformed bacteria were plated on a 
culture plate (10cm of diameter) in LB agar medium containing 
ampicillin 250mg/mL to select the transformed colonies. After 
incubation overnight at 37°C the plates were stored at 4°C. 
 
3.4. Isolation of plasmid DNA using Qiagen® Midi Kit 
A single colony from the selective plates was isolated and inoculated 
in 50mL of LB medium containing ampicillin 250mg/mL as selective 
antibiotic. The incubation was carried out overnight at 37°C in water 
bath with vigorous shaking. The bacterial cells were harvested by 
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centrifugation and the pellet was resuspended in buffer P1 containing 
50mM Tris·Cl, pH=8.0; 2–8°C, 10mM EDTA; 100µg/ml RNase A, 
then treated whit a lysis buffer P2 containing 200mM NaOH, 1% SDS 
(w/v) 15–25°C. Neutralization buffer P3 was added (3.0M potassium 
acetate, pH=5.5 15–25°C or 2–8°C) in order to promote precipitation 
of genomic DNA, proteins and cell debrids. After 2 steps of 
centrifugation at 9384xg and one filtration with miracloth, the 
supernatant was applied to an equilibrate Qiagen-tip using 
equilibration buffer (750mM NaCl; 15–25°C 50mM MOPS, pH=7.0; 
15% isopropanol (v/v); 0.15% Triton® X-100 (v/v)) and allowed it to 
empty. The tip was washed once with wash buffer (750mM NaCl; 15–
25°C 50mM MOPS, pH=7.0; 15% isopropanol (v/v); 0.15% Triton® 
X-100 (v/v)) and the DNA eluted with Elution Buffer (1.25M NaCl; 
15–25°C 50mM Tris·Cl, pH=8.5; 15% isopropanol (v/v)). The DNA 
was precipitated, first with isopropanol and after centrifugation, with 
the more volatile 70% ethanol. The pellet of plasmid DNA was 
resuspended in MilliQ water. 
 
3.5. Quality and concentration of plasmid DNA 
DNA concentration was determined by UV-spectrophotometry at 
260nm using an Eppendorf BioPhotometer. The ratio 260/280nm and 
260/230nm were also measured to check contamination by protein and 
solvent, respectively. DNA purity was checked using the restriction 
enzyme Hind III provided by Invitrogen, in order to exclude genomic 
DNA contamination. All samples with enzyme treatment and without 
restriction enzyme were checked performing Agarose gel electrphoresis 
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containing 1% agarose, TAE buffer and Ethidium bromide for 
visualisation of DNA by UV-light using a Biorad detector. 
 
3.6. Cell culture 
HEK-293 cells, purchased from Invitrogen (Carlsbad, CA) were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% of Newborn Bovine Serum (NBS), 50IU/mL of penicillin and 
50µg/mL streptomycin. Cells were grown in a humidified incubator at 
37°C with 7% of CO2 and subcultured by trypsinization twice weekly. 
 
3.7. Calcium phosphate transient transfection 
One day before calcium phosphate transfection, HEK-293 cells were 
split (1:6) in order to have 50-60% of confluence the next day. A 
solution of sterile MilliQ water, CaCl2 1M, and plasmid DNA having 
the construct of interest was mixed in a falcon tube. After 1-2 minutes, 
HBBS (280nM NaCl, 10nM KCl, 1.5mM Na2HPO4, 50mM HEPES, 
pH=7.05) was added drop wise. After 1 minute 1mL of the DNA-
mixture was added to the cells (10cm plate). Incubation at 37°C with 
7% CO2 was performed and the cell harvested 48 hours post-
transfection. 
 
3.8. Polycation polyethylenimine (PEI) transient 
transfection 
HEK-293 cells were transiently transfected with the polycation 
molecule PEI. Different plasmid DNA concentrations were used: 1, 2.5 
and 5µg to a total amount of 5, and 7.5µg and 10µg to a total volume of 
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10µg per 250µL of DNA. pcDNA 3.1 (-) plasmid was used as empty 
control plasmid DNA, lacking the construct of interest. A total 
DNA/PEI ratio of 1:6 was used. A sterile PEI solution of 1mg/mL and 
NaCl 150mM were prepared. A DNA mixture was used adding plasmid 
DNA to a total volume of 250µL NaCl 150mM. DNA and PEI 
solutions were mixed well and incubated for 20 minutes at room 
temperature (RT). Fresh medium was added to the cells and 500µL of 
transfection mix were added to the cells having 50-60% of confluence 
(1.4-1.8 million cells/10cm dish were seeded the day before). 
Transfected cells were collected after 48 hours. 
 
3.9. ELISA: Enzyme Linked Immunoabsorbent Assay to 
check receptor expression 
The Immunoabsorbent Assay was performed 48 hours after 
transfection. 24 hours after transfection a 96-well plate was treated for 
30 minutes at RT with Poly-D-lysine 0.1mg/mL. 100000 cells/100µL in 
culture medium were seeded plate and incubated at 37°C, 7% CO2 for 
24 hours. After incubation the medium was removed and 100µL of 
primary antibody rabbit-HA-tag EPITOPE (1:5000 in DMEM) was 
added. After 30 minutes of incubation at 37°C, 7% CO2 and a washing 
step, using DMEM/HEPES 25mM 100 µL, a solution of Goat-anti-
Rabbit mAb used at 1:5000 dilution in empty DMEM was added. After 
that, the incubation step was carried out at 37 °C and 7% CO2 for 30 
minutes. The medium was removed and the plate was washed twice 
with 100µL PBS warmed at 37°C. The wells were dried for half an 
hour and incubated for 5 minutes in dark covered in aluminium foil 
after addition of 3,3’,5,5’-Tetramethylbenzidine (TMB). The reaction 
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was stopped with 100µL of H3PO4 1M and the absorbance was 
measured at 450nM after 5 minutes using Victor 2V plate reader from 
Perkin Elmer. 
 
3.10. Membrane preparation from transient transfected 
HEK- 293 cell lines for binding studies 
The recombinant HEK-293 cells expressing either wilde type hCCR2 
and the mutants were harvested after 48 hours after transfection. The 
medium was aspirated and the cells were removed from the plates by 
scraping into 5mL of PBS. The membrane suspension was centrifuged 
at 700g for 5 minutes. The supernatant was discarded and the pellet was 
kept on ice. The pellet was homogenized in a volume (about 20mL for 
30 plates) of 50mM Tris-HCl and 5mM MgCl2, pH=7.4 with the Ultra 
Turrax homogenizer (IKA-Werke GmbH & Co. KG, Staufen, 
Germany). The membrane suspension was centrifuged at 100000 x g in 
the Optima LE-80K ultracentrifuge (Beckman Coulter, Inc., Fullerton, 
CA) with a Ti 70 rotor at 4°C for 20 minutes. The pellet was 
resuspended in 10mL of 50mM Tris-HCl and 5mM MgCl2 buffer and 
the homogenization and centrifugation step was repeated. Finally, the 
pellet was resuspended in 50mM of Tris-HCl buffer and 5mM MgCl2. 
Aliquots of 100 and 250µL were stored at -80°C. Membrane protein 
concentrations were measured using the BCA (bicinchoninic acid) 
method [53]. 
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3.11.  Equilibrium radioligand binding assays 
3.11.1. 125I-CCL2 Binding Assays 
Binding assays were performed in a 100µL reaction volume 
containing 50mM Tris-HCl (pH=7.4), 5mM MgCl2, 0.1% CHAPS 
assay buffer, membranes at a concentration of 25µg. Nonspecific 
binding was determined with 100nM CCL2. The endogenous iodinate 
compound 125I-CCL2 (Kd=0.068nM [54]) was used as radioligand in a 
range of concentration 0.1-0.23nM, between twice or fourth times the 
Kd value. Binding was allowed to proceed for 150 minutes at 37°C of 
incubation. Incubation was terminated by addition of 50mM Tris-HCl 
(pH=7.4), 5mM MgCl2, 0.05% CHAPS, 0.5M NaCl as ice-cold wash-
buffer. Separation of bound from free was performed under reduced 
pressure using a Brandel harvester, by rapid filtration through a GF/B 
filter precoated on 0.25% of PEI solution in 50mM Tris-HCl 
(pH=7.4), 5mM MgCl2 in order to reduce non specific binding. Filters 
were washed three times with ice-cold wash-buffer and collected in γ-
tubes. Scintillation fluid was not required for the iodinate radioligand 
and the filter-bound radioactivity was counted with Perkin-Elmer’s 
Wallac Wizard 1470 automatic gamma counter (Perkin-Elmer). Each 
data point for nonspecific and specific binding was done in duplicate 
for the screening of each mutation and the wilde type 
 
3.11.2. [3H]-V-10-5191 Binding Assays 
Binding on human CCR2 receptor was determined on membranes 
from HEK-293 cells expressing the human receptors, using [3H]-V-
10-5191 (Kd=5.00 nM [55] ) as radioligand. Membranes containing 25 
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or 40µg of proteins were incubated in a total volume of 100µl of 
50mM Tris-HCl (pH=7.4), 5mM MgCl2, 0.1% CHAPS assay buffer 
and [3H]-V-10-5191 (final concentration 12.2-16.5nM) for 2 hours at 
25°C of incubation using a 96-well plate. Nonspecific binding was 
determined in the presence of 10µM V-10-5191. Incubation was 
terminated by rapid filtration over a 96-well GF/B filter plate under 
reduced pressure using a PerkinElmer Filtermate-harvester 
(PerkinElmer, Groningen, The Netherlands). Filters were washed ten 
times by addition of 50mM Tris-HCl (pH=7.4), 5mM MgCl2, 0.05% 
CHAPS ice-cold buffer and 25µL of Microscint scintillation cocktail 
(PerkinElmer) was added to each well. After 2 hours of incubation, 
the filter- bound radioactivity was determined by scintillation 
spectrometry using P-E 1450 Microbeta Wallac Trilux liquid 
scintillation counter (PerkinElmer) by using uncoated 96-well GF/B 
filter plates. As described in the previous assay entitled “125I-CCL2 
Binding Assay”, each data point was done in duplicate for the 
screening of each mutation. 
 
3.11.3. [3H]-V-10-5299 Binding Assays 
Assay conditions were similar to those described for [3H]-V-10-5191 
binding assay. Nonspecific binding was determined using 10µM of the 
corresponding unlabelled compound V-10-5299. The radioligand 
binding was performed using [3H]-V-10-5299 (Kd=5.8nM [54] ) (final 
concentration 2.5-3nM). The experiment was terminated as described 
in the section entitled “[3H]-V-10-5191 Binding Assay” using 
uncoated 96-well GF/B filter plates. 
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3.12. Data analysis 
All data was analysed using Microsoft Office Excel 2003 and 
GraphPad Prism v.5 (GraphPad Software Inc., USA). They were 
expressed as the mean ± SEM. Data from the binding of radioligands 
from hCCR2 WT and mutants were reported as the mean ± SEM from 
three separates experiments. 
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Chapter 4 
Results and discussion 
 
4.1. Gene delivery system: comparison between two 
transfection techniques in HEK-293 cells for the 
hCCR2 chemokine receptor through binding assays 
Two different transfection techniques were compared: the first one 
was calcium phosphate transfection and the second one was carried 
out using the polycation molecule PEI (25kDa). For both transfection 
methods, common conditions are crucial for a favourable outcome. 
Cells health, cells confluence at 50-60%, quality and quantity of 
plasmid DNA, medium, all of them are important parameters to 
perform a successful experiment [56]. Previous studies suggested that 
for calcium phosphate transfection, 10µg of plasmid DNA was an 
optimal amount to yield high receptor expression. However, binding 
of 125I-CCL2 to the transfectants could not be detected. Therefore, in 
order to have a better expression of WT and mutant constructs of the 
hCCR2b receptor in this study another transfection method was 
included using polyethylenimine (PEI). The first PEI transfection was 
performed using 1µg, 2.5µg and 5µg of plasmid DNA. Receptor 
expression was checked using three different radioligands: the 
endogenous ligand 125I-CCL2 (KD=0.068nM [54]), and two small 
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molecules antagonist radioligands: [3H]-V-10-5191 and [3H]-V-10-
5299 (KD=5.0nM and 5.8nM respectively, [54] [55] ) (Fig. 5). 
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Fig. 5. Structure of small molecule antagonists of CCR2 Chemokine receptor: V-10-5191 also 
recognised as INCB3344 (A), V-10-5299: active (R)-4-Acetyl-1-(4-chloro-2-fluorophenyl)-5-
cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one and inactive (S)-4-Acetyl-1-(4-chloro-2-
fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one enantiomers (B). 
 
Fig. 6 shows the specific binding of the three different molecules and 
gives an indication of a different efficiency in receptor expression. For 
calcium phosphate transfection, the tritium radioligands (blue and red 
bar in the graph) showed a high window in specific binding of 
hCCR2b. However, 125I-CCL2 specific binding was not detected 
(green bar in Fig. 6). For PEI transfection high levels of specific 
binding of [3H]-V-10-5191 and [3H]-V-10-5299 were also detected 
but differently from what observed with the previous experiment, 125I-
CCL2 specific binding was significantly measured. Furthermore, the 
data concerning PEI transfection revealed that an increase in the 
amount of plasmid DNA is related to higher receptor expression. The 
maximum amount of DNA for the calcium phosphate and PEI 
transfection was 10µg and 5µg respectively. These data suggested that 
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in our study PEI transfection seemed to be more efficiently in 
HEK293 cells. 
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Fig. 6. Displacement from calcium phosphate and PEI transfected HEK-293 cells (40µg/25µL 
membranes). The picture shows the specific binding of three radioligands: 125I-CCL2 0.15nM 
(green), [3H]-V-10-5191 16nM (blue), [3H]-V-10-5299 2.43nM (red). WT hCCR2 10µg is 
correlated to calcium phosphate transfection and WT hCCR2 1µg, 2.5µg and 5µg to PEI 
transfection. Mock is used as negative control. 
 
4.2. Optimization of PEI transfection and evaluation 
through binding assays 
A subsequent PEI transfection was performed on HEK-293 cells using 
a new WT hCCR2b DNA construct having a 3xHA-tag epitope at the 
N-terminus domain. In order to verify if also in this case, 5µg was the 
optimal concentration of plasmid DNA, the transfection was 
performed increasing the amount of plasmid DNA at 7.5µg and 10µg. 
The ratio DNA/PEI was maintained at 1:6. Data showed that 5µg was 
not the optimum concentration. In fact, using radioligand binding 
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assays higher levels of receptors expression were detected at 7.5µg 
and 10µg. Only for this transfection, an Enzyme linked 
immunoabsorbent assay (ELISA) was performed to check receptor 
expression (Fig. 7) using the appropriate kit as described in the section 
of “Material and methods”. 
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Fig. 7 ELISA from PEI transfected HEK-293 cells: absorbance detected at 450nm for mock 
(negative control), WT hCCR2b in HEK-293 cells transfected with 1µg, 2.5µg and 5µg of plasmid 
DNA. 
 
Comparing the absorbance at 450nm of the cells transfected with the 
mock and the construct of 5 µg and 2.5µg an increase of 2.6 and 1.5 
fold was observed respectively. In contrast, the cells transfected with 
7.5µg and 10µg did not show a high percentage of life (checked with 
colorant Trypan Blue in a BioRad Reader) and this caused a 
detachment from the wells. This aspect did not allow performing 
ELISA for the cells transfected with higher concentration of plasmid 
DNA. However comparing the first PEI transfection with the second, 
performed with the HA-tag epitope WT hCCR2b, a decrease in the 
maximal signal was observed. This suggested that a change in plasmid 
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construct (typology and quality) might effect on intensity of receptor 
expression. Moreover, PEI transfection performed at 10µg was carried 
out using a doubling in PEI amount (ratio DNA/PEI = 1:6). Even if 
the cells expressed significantly the receptor, a treatment with a ratio 
PEI/DNA 1:6 using high DNA concentration, showed a decrease in 
growing. These data suggested that the PEI amount added could be 
toxic for health cells [57]. Although high levels of cell death occurred 
two days after transfection, the receptor was still highly expressed. In 
fact as Fig. 8 shows the most efficient expression was observed for the 
constructs of 7.5µg and 10µg. The 125I-CCL2 manifested a 
proportional increase in specific binding reaching the highest window 
at 10µg. The tritium labeled antagonists [3H]-V-10-5191 showed a 
decreased of 2.5-3 fold in specific binding compared to the 
endogenous ligand. The radioligand [3H]-V-10-5299 showed the 
lowest signal with a decrease of more than 5 fold compared to 125I-
CCL2 but still considerable to detect the construct of 10µg as the most 
effective. Therefore, subsequent transfections of WT, mock 
pcDNA3.1(-) and the 10 mutants were carried out with 10µg of 
plasmid DNA. 
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Fig. 8 Displacement from PEI transfected HEK cells (25µg/25µL membranes). The picture shows 
the specific binding of the three radioligand: [125I]-CCL2 0.22nM (green), [3H]-V10-5191 12nM 
(blue), [3H]-V10-5299 3.15nM (red) on WT hCCR2 using different amount of DNA: 1, 2.5, 5, 7.5 
and 10µg and mock as negative control. 
 
4.3. Evaluation of hCCR2b mutants and WT expression 
through binding assay and identification of the 
binding site of V-10- 5191 and V-10-5299 on hCCR2 
In this study we carried out the expression of the WT and ten mutants 
of hCCR2b, with a relevant aim not yet evaluated in literature: 
elucidate the binding site of two small molecule, non peptidergic 
ligands, antagonists of hCCR2 chemokine receptor: V-10-5191 
recognised as INCB3344 [55] [58] and V-10-5299. As reported in 
literature, V-10-5191 or INC3344 was effective in lowering 
macrophage in target tissues and in suppressing development of 
disease models such as: mouse model of multiple sclerosis, rat model 
of inflammatory arthritis and mouse model of obesity [58]. Moreover, 
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the molecule exhibited IC50 of 5.1nM (hCCR2) and 9.5nM (mCCR2) 
in binding affinity and 3.8nM (hCCR2) and 7.8nM (mCCR2) in 
chemotaxis activity [58]. It also showed a moderate hERG binding 
activity, a good oral bioavailability and a promising pharmacokinetics 
profile in mouse [58]. Less study are present in literature for the 
molecule V-10-5299 but has been reported that the R-active 
enantiomer of the molecule used in a treatment of nerve-injured rats 
showed reversal of tactile hyperalgesia [51]. The present study 
focused his attention on the binding site of these two molecules using 
a mutagenesis approach. The effects of mutations on receptor 
expression have been evaluated with the use of three radiolabeled 
compounds: 125I-CCL2, [3H]-V-10-5191 and [3H]-V-10-5299 and 
described in the following sections. 
 
4.3.1. Effect of hCCR2b mutations on binding of the 
labelled endogenous ligand 125I-CCL2  
The ability of each mutant to bind 125I-CCL2 was examined and 
except for some mutants, a specific binding was detectable (Table 1) 
(Fig 9). For mutants Y49A1.39, W98A2.60, Y120A3.32, E291A7.39 the 
specific binding was significantly reduced, lower than 30% compared 
to WT. For F125A3.37, I263A6.55, E291Q7.39 the signal was lower than 
50%. Differently from what observed for other mutants, H121A3.33 
showed an increase in specific binding while for I208A5.44 and 
T292V7.40 no notable changes compared to WT were observed (Fig. 
9). According to literature [59] these data showed that the upper part 
of TM1, TM2, TM3 and TM7 are important for the binding to the 
endogenous ligand. Mutations of the aromatic residues such as 
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Tyr491.39, Trp98A2.60, Tyr120A3.32 suggested that hydrophobic 
interactions or H-bond affect the binding of CCL2 to TM1, TM2 and 
TM3 of CCR2. Electrostatic interactions are more involved in the 
binding to TM7. Mikhail et al. [60] sustained that reversing the 
negative charge in Glu2917.39 to a positive charge in lysine, ligand 
binding was completely abrogated. In this study the mutation of the 
charged side chain of the glutamic acid into the hydrophobic alanine 
caused a loss in specific binding more than the substitution to a polar 
glutamine. Other mutants did not showed a significant influence on 
the binding except for H121A3.33. The loss of a positive charge of the 
hystidine seemed to stabilize the binding of the ligand to the receptor. 
These are in accordance with the data obtained by Hall et al. [52]. In 
fact, a decrease in IC50 of 2.27 fold compared to WT was described 
for H121A3.33 and a displacement less than 50% was observed for 
Tyr491.39, Trp98A2.60, Tyr120A3.32 and Glu2917.39. What mentioned 
above suggested that mutants H121A3.33 increased the affinity of 
CCL2 for the receptor, whereas the seconds produced a decrease. 
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[3H]-V-10-5191
[3H]-V-10-5299
 
Fig. 9 Displacement from PEI transfected HEK cells. The picture shows the percentage of specific 
binding of the three radioligand: 125I-CCL2 (green), [3H]-V10-5191 (blue), [3H]-V10-5299 (red) 
on mock (negative control), WT and 10 mutants of hCCR2b (using 10µg of plasmid DNA). 
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4.3.2. Effect of hCCR2 mutations on binding of 
labelled antagonists [3H]-V-10-5191 and [3H]-
V-10-5299  
Fig. 9 shows that the two antagonists [3H]-V-10-5191 and [3H]-V-10-
5299 have completely a different profile. The results of this 
experimental section are summarized in Tab. 1. The binding of the 
first ligand is considerable influenced. In fact, for mutants Y49A1.39, 
W98A2.60 and T292V7.40 no specific binding was measured. Mutants 
Y120A3.32, E291A7.39 and E291Q7.39 were also significantly effected 
showing a specific binding lower than 30%. Moreover H121A3.33 and 
I263A6.55 showed a decrease less than 50%. Conversely, mutants 
F125A3.37 and I208A5.44 did not produce a loss in binding or at least in 
a very negligible percentage, suggesting that they are localized outside 
the binding pocket. Finally, as reported by the red bar in Fig. 9, for the 
[3H]-V-10-5299 ligand a high value of standard deviation was 
obtained and did not allow us to identify the influence of the mutants 
on specific binding. 
 
4.3.3. Orthosteric or allosteric compound? 125I-CCL2 
and [3H] labelled small antagonists binding in 
comparison 
Divergence and similarities can be observed in the binding mode of 
[3H]-V-10-5191 (blue bar in Fig. 9) compared to the iodinate CCL2. 
As for 125I-CCL2, mutants Y49A1.39, W98A2.60 showed completely a 
lack in specific binding. The ability of Y120A3.32, E291A7.39 and 
E291Q7.39 mutants to bind [3H]-V-10-5191 was also reduced. 
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Differently from 125I-CCL2, mutant T292V7.40 affected clearly [3H]-V-
10-5191 binding and H121A3.33 also lowered the specific binding of 
the tritium radioligand to the receptor. Data summarized in Tab. 1 
shows for the molecule V-10-5191 a series of chemical interactions 
that cooperate strongly with these residues of interest. 
 
Tab. 1 Summary of displacement of the three radioligands in use from mutants of CCR2: 
↓↓↓ specific binding less than 30% compared to WT, ↓↓ specific binding less than 50% compared 
to WT, ↓ specific binding lower than WT, Nil negligible specific binding, mention ↑, - specific 
binding approximately as wild type. 
Construct 125I-CCL2 [3H]-V-10-5191 [3H]-V-10-5299 
Y49A ↓↓↓ Nil - 
W98A ↓↓↓ Nil - 
Y120A ↓↓↓ ↓↓↓ ↑ 
H121A ↑ ↓↓ ↑ 
F125A ↓↓ ↓ - 
I208A ↓ - - 
I263A ↓↓ ↓↓ ↓ 
E291A ↓↓↓ ↓↓↓ - 
E291Q ↓↓ ↓↓↓ ↑ 
T292V ↓ Nil - 
 
They were further explored in a homology model of CCR2. The most 
relevant amino acids and binding interaction are represented in Fig. 
10. The homology model suggested that residue Tyr491.39 could be 
involved in hydrogen bonds with the amide nitrogens (distance ~ 5Å) 
of the small molecule and could be stabilized with π-π interaction by 
the residue W982.60. Glu2917.39 is known from literature to interact 
with the pyrrolidine nitrogen through electrostatic interactions [52]. 
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Tyr1203.32 forms an important interaction with the ethoxy group of the 
pyrrolidine ring. Other residues such as His1213.33 that also showed a 
decrease in specific binding of [3H]-V-10-5191 from hCCR2, could 
interact through van der Waals interactions. These data showed that 
the radioligands 125I-CCL2 and [3H]-V-10-5191 overlap some 
residues. They could share a common binding site on the receptor 
suggesting that molecule V-10-5191 could be an orthosteric 
antagonist of human chemokine receptor CCR2. For the molecule V-
10-5299 it was difficult to detect the residues involved in the binding. 
However data showed for all the mutants, suggested that the two 
molecules have a different binding site. The size of the antagonists 
(∼600Da) is smaller compared to the endogenous ligand (∼8600Da) 
and several new mutations could affect the binding of the molecule to 
the receptor adding new information on the binding mode of the 
molecule that could be in the transmembrane region but also  
extracellular or intracellular. The sulfonamide antagonists of CCR4 
receptor, e.g., synthetized by Glaxo and described by Andrew et al. 
[35], showed an intracellular binding site. This binding site is located 
close to the site of G protein-coupling to the receptor, and therefore 
the presence of antagonist at this site could prevent activation of G 
protein [54]. Recently, It has been demonstrated that the molecule V-
10-5299 recognised as CCR2-RA-[R] has a similar binding site with 
the molecule JNJ-27141491, previously described [45], and they 
inhibit CCR2 with a similar mechanism [54]. Mutations localized in 
the intracellular region of hCCR2b might elucidate the hypotesis of an 
intracellular binding site for V-10-5299. For this reason in order to 
assert if the molecule is an orthosteric or allosteric antagonist further 
investigations are required. 
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Fig. 10 Residues involved in the binding of V-10-5191 on CCR2 and binding interactions. 
 
4.4. Comparison of the interhelical contacts between 
Teijin and V-10-5191 binding on hCCR2 receptor 
In previous study reported by Hall et al. [52], the mutants analyzed in 
this study were considerate to investigate the binding site of other two 
molecules, dual antagonists of chemokine receptor CCR2 and CCR5: 
TAK-779 and Teijin compound 1. Comparing the chemical structure 
of Teijin (Fig. 11B) and V-10-5191 is possible to notice some 
common structural features. In Fig. 11A residues His1213.33 and 
Ile2636.55 show favourable van der Waals interaction with the 2,4-
dimethyphenil moiety of Teijin compound 1. Thr2927.40 forms a 
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hydrogen bond to the carbonyl attached to the trifluorotoluyl ring and 
Glu2917.39 shows electrostatic interaction with the pyrrolidine 
nitrogen. In contrast from what predicted by the homology model 
from Hall et al. Y120A3.32 showed no significant interaction for Teijin 
compound 1. In our study Tyr1203.32 seems to have a stronger effect 
on V-10-5191. According to our homology model this could be due to 
the ethoxy group on the pyrrolidine ring that can interact with 
Y120A3.32 and represents one of the structural differences between the 
two molecules. 
 
 
 
Teijin compound 1 
 
Fig. 11 Residues in binding pocket of Teijin compound 1 (A) and chemical structure of Teijin 
compound 1 (B) [52]. 
 
 
 
A 
their binding sites can only partly overlap. For CCR2, several
mutagenesis studies have provided evidence for the binding of
small-molecule antagonists in the major and minor pocket
(Mirzadegan et al., 2000; Berkhout et al., 2003; Hall et al.,
2009). These ligands often contain a positively charged basic
nitrogen that interacts with the conserved negatively charged
glutamic acid residue (E291) in TM7, which is directly located
between the major and minor binding pocket (Rosenkilde and
Schwartz, 2006). In addition, several other CCR2 antagonists
have been developed that do not possess such a basic nitrogen,
and their binding site remains to be elucidated (Struthers and
Pasternak, 2010). As there is growing evidence of multiple
ligand binding sites for other chemokine receptors, we sought to
determine whether CCR2 contains several binding sites as well.
To gain a better understanding of the interaction of CCR2
and its ligands, we examined the binding sites and pharmaco-
logical properties of six chemically distinct CCR2 antagonists.
These antagonists are RS504393 (6-methyl-19-[2-(5-methyl-2-
phenyl-4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,49-piperidin]-
2(1H)-one) (Mirzadegan et al., 2000), BMS22 (2-[(isopropylami-
nocarbonyl)amino]-N-[2-[[cis-2-[[4-(methylthio)benzoyl]amino]cy-
clohexyl]amino]-2-oxoethyl]-5-(trifluoromethyl)benzamide)
(Cherney et al., 2008), Teijin compound 1 (N-[2-[[(3R)-1-[(4-
chlorophenyl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-
(trifluoromethyl)benzamide) (Moree et al., 2008), INCB3344
[N-(2-(((3S,4S)-1-((1r,4S)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxy-
cyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-
(trifluoromethyl)benzamide] (Brodmerkel et al., 2005), the
(R) isomer CCR2-RA-[R] (Bhangoo et al., 2007), and JNJ-
27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-
thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester]
(Buntinx et al., 2008) (Fi . 1). In this study, for the first time,
we provide evidence for two distinct binding sites of small-
molecule antagonists at the CCR2 receptor. We also discuss
the possible biased antagonism of some of the compounds.
This work contributes to a better understanding of the
nature of the interactions of diverse ligands at the CCR2
receptor.
Materials and Methods
CCL2 was purchased from PeproTech (Rocky Hill, NJ), and the
CCR2 antagonists BMS22 (Cherney et al., 2008), RS504393 (Mirzadegan
et al., 2000), and Teijin compound 1 (Moree et al., 2008) were ob-
tained fromTocris Bioscience (Bristol, UK). INCB3344, JNJ-27141491,
and CCR2-RA-[R] were synthesized in-house as described previously
(Xue et al., 2004; Brodmerkel et al., 2005; Zou et al., 2007; Doyon
et al., 2008). [3H]INCB3344 (specific activity 32 Ci mmol21) was
custom-labeled by ViTrax (Placentia, CA), by means of direct titration
of the parent ligand. Notably, INCB3344 was labeled as a racemic
mixture of the two isomers N-(2-(((3S,4S)-1-((1r,4S)-4-(benzo[d][1,
3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-
oxoethyl)-3-(trifluoromethyl)benzamide and N-(2-(((3R,4R)-1-((1r,4R)-
4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-
yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide,butonly the first iso-
mer had sufficient affinity to label CCR2 in our experiments (see later
discussion herein). The racemic radioligand [3H]CCR2-RA (specific
activity 63 Ci mmol21) was custom-labeled by ViTrax, for which a
dehydrogenated precursor of CCR2-RA was provided. CCR2-RA was
labeled as a racemic mixture of the two isomers (R)-4-acetyl-1-(4-chloro-
2-fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one
and (S)-4-acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one. 125I-CCL2 (2200 Ci/mmol) and guano-
sine 59-O-(3-[35S]thio)triphosphate ([35S]GTPgS) (1250 Ci/mmol) were
purchased from PerkinElmer (Waltham, MA). Bovine serum albu-
min (fraction V) was purchased from Sigma-Aldrich (St. Louis, MO).
Bicinchoninic acid (BCA) and BCAprotein assay reagentwere obtained
from Pierce Chemical Company (Rockford, IL). Tango CCR2-bla U2OS
cells stably expressing humanCCR2 (U2OS-CCR2) were obtained from
Invitrogen (Carlsbad, CA). All other chemicals were obtained from
standard commercial sources.
Cell Cultures. U2OS-CCR2 cells were cultured in McCoy’s 5a
medium supplemented with 10% fetal calf serum, 2 mM glutamine,
0.1 mM nonessential amino acids, 25 mM HEPES, 1 mM sodium
pyruvate, 100 IU/ml penicillin, 100 mg/ml streptomycin, 100 mg/ml
G418, 50 mg/ml hygromycin, and 125 mg/ml zeocin in a humidified
atmosphere at 37°C and 5% CO2. Cells were subcultured twice weekly
at a ratio of 1:6 on 10-cm ø or 15-cm ø plates by trypsinization.
Cell Membrane Preparation. Cells were detached from 15-cm
ø plates by scraping into 5 ml of phosphate-buffered saline and
subsequently centrifuged for 5 minutes at 3000g. The pellets were
Fig. 1. Chemical structures of reference CCR2 small-molecule antagonists.
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Chapter 5 
Conclusion and future prospects 
 
In conclusion, several techniques of transfection on HEK-293 cells 
have been applied in previous works [61] [62] but in the present study 
two different techniques of transfection on HEK-293 cells have been 
examined, showing that PEI transfection is the most efficiently. 
Concerning the use of PEI it could be interesting investigate the range 
of PEI toxicity in this cell line and distinguish which characteristics of 
plasmid constructs could influence receptors expression. Moreover, 
using site-directed mutagenesis and radioligand binding assay it has 
been possible to evaluate receptor expression and analyse the 
importance of some residues involved in the binding of CCR2 
antagonists. In particular for the molecule V-10-5191 has been 
discovered that the conserved residues Tyr491.39, Trp98A2.60, 
Thr2927.40, but also Y120A3.32 and Glu2917.39 are significant for the 
binding on the receptor. According to literature, also some residue has 
been found to be crucial for CCL2 binding. These data allow 
identifying in TM1, TM2, TM3 and TM7 the binding pocket of V-10-
5191 also recognized as “minor binding pocket” for other small 
molecules antagonists of chemokine receptor [34]. Using binding 
assay it would also be advisable evaluate the Ki for the mutants that 
affect mainly antagonists binding and through functional assay (e.g. 
GTPγS assay) determine their EC50 (half maximal effective 
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concentration). In order to better investigate the binding pocket of 
antagonists of chemokine receptor, several other mutants have been 
identified. One approach is to study other chemokine receptors and 
find out some mutants important in the binding. After the alignment of 
the sequence coding for WT human CCR2 and other chemokine 
receptor (appendix) some residues Asp782.40, Ser1012.63, Arg2065.42, 
Tyr3057.53, Lys3118.49, Lys180 and Lys183 have already been 
identified to be important for antagonists binding. They are localized 
in TM2, TM5, TM7, helix 8 and in the second extracellular loop, 
respectively. In particular Lys3118.49 seems to be very promising to 
investigate the binding of V-10-5299 suggesting an intracellular 
binding site for the molecule. Finally, looking into the effect of these 
mutations on ligand affinity to the receptor, It could be possible 
propose the synthesis of new molecules antagonists of chemokine 
receptor having stronger interactions with the receptor. This might be 
translated with a better affinity and efficacy, or a longer residence 
time that hopefully will lead to a therapeutic improvement.  
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